OrbiMed Advisors LLC
601 Lexington Avenue
(at 53rd Street), 54th Floor
New York
New York
10022-4629
United States
Tel: 212-739-6400
Website: http://www.orbimed.com/
58 articles about OrbiMed Advisors LLC
-
Magenta Medical Closes $55M Funding Round Led by OrbiMed
5/3/2023
Magenta Medical, developer of the world's smallest heart pump, announced a $55M financing round led by global healthcare investment manager OrbiMed, with participation from existing investors New Enterprise Associates, Pitango VC, and ALIVE - Israel HealthTech Fund.
-
San Francisco-based Terremoto Biosciences launched with $75 million in Series A financing from OrbiMed and Third Rock Ventures as it develops highly targeted, small-molecule medicines.
-
Sionna hit the ground with a pipeline of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in CF patients.
-
Money on the Move: February 9 – 15
2/16/2022
As the market seems to be taking a turn against biotech stock, more companies are opting for private funding instead of going public for the moment. And VC firms are happy to jump in. -
ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.
-
The funds will be used to advance the firm's precision oncology research efforts and pipeline, particularly those involving the creation of alteration-specific therapies.
-
Dr. Tal Zaks and Dr. Sheila Gujrathi Join OrbiMed
11/1/2021
OrbiMed is pleased to announce two new team additions who are among the global biotechnology industry’s most talented and capable professionals.
-
The proceeds will be used for the companies' growth, to help develop their platforms and advance their pipelines.
-
Several biopharma companies announced Series B financing rounds or additional investment raises. Here’s a look.
-
The combined company out of the Humacyte SPAC will be called Humacyte and is expected to trade shares of common stock and warrants on the Nasdaq Global Select Market.
-
The two companies announced their exclusive collaboration that will harness Kumquat’s small molecule immuno-oncology platform's capabilities to discover novel clinical candidates.
-
Through its OrbNet platform, Entos has already forged various partnerships with investors and leaders in the pharmaceuticals, materials, and chemicals industries.
-
German biotechnology firm LEUKOCARE, which has operations in Milford, Connecticut, has announced the closing of $17.5 million financing round from New York investment firm Petrichor Healthcare Capital Management.
-
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
-
SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. The company plans to use the money to advance its pipeline.
-
OrbiMed Raises $3.5 Billion Across Private Investment Funds
3/1/2021
OrbiMed, a leading life sciences investment firm, announced $3.5 billion in commitments for its latest private investment funds, including $1.5 billion for OrbiMed Private Investments VIII, $800 million for OrbiMed Asia Partners IV, and $1.2 billion for OrbiMed Royalty & Credit Opportunities III. Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds
-
VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases
10/15/2020
VectivBio's investor syndicate expands to include Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management
-
Prelude Therapeutics Announces Closing of $50M Series C Financing
8/24/2020
Prelude Therapeutics, a privately-held, clinical-stage precision oncology company, announced that it has completed a $50 million Series C financing round led by Prelude’s two existing institutional investors, including OrbiMed Advisors LLC, and a new investor, Fidelity Management & Research Company LLC.
-
Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease
12/12/2019
Led by Chief Executive Officer Howard Federoff, M.D., Ph.D., Former Vice Chancellor for Health Affairs and Chief Executive Officer of the University of California Irvine Health System
-
Repare Therapeutics Announces US$82.5 Million Series B Financing
9/4/2019
Repare Therapeutics, a precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, announced the completion of a US$82.5 million Series B financing.